- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
B-K releases scanners, transducers
The Denmark-based subsidiary of Analogic, B-K Medical, exhibited several new ultrasound technologies at the American College of Surgeons Annual Clinical Congress in October. Topping the introductions were the Hawk 2102 EXL color scanner, the company's
The Denmark-based subsidiary of Analogic, B-K Medical, exhibited several new ultrasound technologies at the American College of Surgeons Annual Clinical Congress in October. Topping the introductions were the Hawk 2102 EXL color scanner, the company's new flagship ultrasound scanner, and the new black-and-white Falcon 2101 EXL. Both incorporate advanced focusing and proprietary detector technology, large monitors, sophisticated video interface, and fully integrated 3D option. The Hawk also boasts improved Doppler functionality. Vascular scanning is enhanced by a new, dedicated transducer, dubbed type 8812, which combines deep Doppler sensitivity with near-field performance. The company also showed a new transducer optimized for breast and musculoskeletal scanning. The probe, which works with B-K's portable Merlin 1101, is pending FDA clearance for musculoskeletal applications.
Two weeks after the conference, the company announced the resignation of Rene Barington as its managing director. Barington held the post for six years.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
